BSM vs MTX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MTX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BSM and MTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BSM and MTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Black Stone Minerals owns mineral and royalty interests rather than operating wells itself. When oil and gas operators drill and produce on Black Stone's acreage, the partnership collects a royalty (a share of revenue off the top) without paying for the rigs, completion work, or ongoing operating expenses. That structure means very little capital spending of its own, low overhead relative to revenue, and cash flow that converts largely into distributions to unitholders. Its asset base is long-lived and gas-weighted: reserves are roughly 70 percent natural gas and around 88 percent proved developed producing, and it holds mineral interests across roughly 16.9 million gross acres plus additional royalty interests, spanning dozens of states.

Full BSM guide

Minerals Technologies Inc. (NYSE: MTX) is a global specialty minerals company built originally out of Pfizer's minerals unit. It is one of the largest producers of precipitated calcium carbonate (PCC) and the world's largest bentonite producer, and it organizes its business into two segments: Consumer & Specialties (household and personal care products such as cat litter, personal care, fabric care, edible-oil purification, plus specialty additives) at roughly 53% of sales, and Engineered Solutions (high-temperature refractory technologies and environmental and infrastructure products) at roughly 47%. The company sells into paper, packaging, construction, automotive, foundry, steel, and consumer markets across more than 35 countries.

Full MTX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BSM drivers: Capital-light royalty model; Production inflection into 2026.
• MTX drivers: Diversified specialty-minerals franchise; Return to growth and margin recovery.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Royalty income rises and falls with oil and especially natural gas prices, so revenue and distributions can swing sharply when commodity prices drop. For MTX, the dominant risk is the talc litigation itself: the reorganization plan must be confirmed and funded, and a large charge (around $290 million booked in 2026) already pressures reported results, with the possibility of adverse rulings or higher-than-expected claim funding.

Pick BSM if you believe its drivers more; MTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BSM and MTX guides.

BSM. For a royalty partnership, the numbers to watch differ from a normal stock. Distributable cash flow (DCF) and the distribution coverage ratio matter more than earnings per share, because the payout is the main reason most investors hold the units: coverage above 1.0x means DCF exceeded the distribution, which suggests the payout has cushion, while coverage near or below 1.0x raises the risk of a cut. The yield looks high partly because the structure passes most cash through, and partly because the income swings with commodity prices. Because BSM is a partnership, you receive a Schedule K-1 (typically by mid-March) rather than a 1099, distributions are largely treated as return of capital that lowers your cost basis, and depletion deductions can shelter part of the income; holding units in an IRA can trigger UBTI complications, so many investors hold them in a taxable account and consult a tax professional.

MTX. MTX trades at roughly 14 times earnings, a discount to the broader chemicals and materials group, which reflects the market pricing in talc-litigation uncertainty rather than weak operations. Revenue of about $2.1 billion generates operating income in the low-double-digit-percent margin range, and Q1 2026 showed both revenue growth and a profit rebound. The valuation gap is the crux of the debate: bulls see a discount that narrows once the litigation is capped, while the reported figures remain distorted by large one-time reserve charges.

Headline figures (approximate, FY2025 results and Q1 2026 results): BSM shows net income (fy2025) ~$299.9 million, adjusted ebitda (fy2025) ~$337.4 million, distributable cash flow (fy2025) ~$300 million, distributions (fy2025) $1.28 per common unit; MTX shows revenue (ttm) ~$2.1B, market cap ~$1.8B, p/e ratio ~14x, q1 2026 revenue ~$547M (up ~11% YoY).

BSM and MTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BSM and MTX exposure against your real portfolio. It is not an investment adviser.